Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Perampanel · 1 trial · 5 indications
Change in suicidal ideation will be assessed 24 hours post-Ketamine infusion using a Scale for Suicidal Ideation, composed of the first five items of the Beck Suicide Inventory + the Hamilton Depression Rating Scale (HAMD-7) suicidality item. The first five items of the Beck Suicide Inventory are rated on a scale of 0-2, and the suicidality item on the HAMD-7 is rated from 0-4. Scores are totaled and will be analyzed as the dependent variable in a mixed-effects model with drug condition (placebo/perampanel) and time (baseline, 24-hour follow up) as within-subject factors.
Changes in depressive symptoms will be assessed 24 hours post-Ketamine infusion using the full Hamilton Depression Rating Scale (HAMD-7), a 7-item survey to assess depression. Scores range from 0-26 with scores indicating full remission (0-3) and partial/non-response (4-26). Scores are totaled and will be analyzed as the dependent variable in a mixed-effects model with drug condition (placebo/perampanel) and time (baseline, 24-hour follow up) as within-subject factors.
| Arm | Type | Description |
|---|---|---|
| Perampanel + Ketamine | EXPERIMENTAL | Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day. |
| Placebo + Ketamine | PLACEBO_COMPARATOR | Participants will receive oral perampanel or placebo, in counterbalanced order, 2.5 hours before a standard, subanesthetic Ketamine infusion (0.5 mg/kg over 40 minutes). Ketamine infusions will be at least three weeks apart. Participants will refrain from caffeine and over-the-counter medication seven days before the infusion day. |
| Name | Type | Description |
|---|---|---|
| Perampanel 6 MG | DRUG | Perampanel will be administered 2.5 hours before Ketamine infusion |
| Ketamine | DRUG | Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration. |
| Placebo | DRUG | Placebo will be administered 2.5 hours before Ketamine infusion |
Inclusion Criteria: * Current depression as indicated by a score greater than 17 on the full Hamilton Depression Rating Scale (HDRS-17) AND current major depressive episode as determined by structured clinical interview (SCID-5) * Current suicidal ideation as indicated by a score ≥ 2 on the HDRS-17...
Top 20 of 29 competitors
Perampanel is an investigational small molecule being studied for Depressive Disorder, including Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, and Suicidal Ideation. It is currently in Phase 2 clinical development and is not yet approved for this use.
Perampanel targets the AMPA receptor, a type of glutamate receptor in the brain. By blocking this receptor, it may modulate excitatory neurotransmission, which is being investigated for its potential impact on depressive symptoms and suicidal ideation.
Perampanel is being developed by National Healthcare Corp. (ticker: NHC). The company is conducting a Phase 2 clinical trial to evaluate the drug for Depressive Disorder and related conditions.
Perampanel is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for any use. The current Phase 2 trial is actively recruiting participants.
Perampanel is being studied in a Phase 2 clinical trial with the identifier NCT05786066, titled 'The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects.' This randomized, double-blind, placebo-controlled trial is recruiting 30 participants in the United States.
Yes, Perampanel 6 MG is another name for Perampanel. The drug is also known by this alternative name, which refers to the 6 milligram dosage form being studied in clinical trials.